FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.
What happened
FDA reviewed Thrivelab's website (https://www.thrivelab.com) in March 2026 and found it offering compounded drug products, including semaglutide. FDA said the site's labels show "thrivelab" as if the company made the drugs when it does not, and that promotional claims such as "Same active ingredient as Ozempic®" and "clinically proven to work" imply the compounded products are FDA-approved when they are not. Because of this, FDA says the products are misbranded (misbranded means the labeling or advertising is false or misleading) and shipping them across state lines is a prohibited act.
What FDA found
The website labels name "thrivelab" on the product label, which suggests Thrivelab made the drug when it did not.
21 C.F.R. § 201.1(h)(2); FD&C Act § 502(a) [21 U.S.C. § 352(a)]The site says the products have the "Same active ingredient as Ozempic®" and "Same active ingredient as Wegovy and Ozempic," which implies FDA approval the compounded drugs do not have.
FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The site claims the products are "clinically proven to work," which FDA says falsely presents the compounded drugs as evaluated for safety and effectiveness.
FD&C Act § 502(bb) [21 U.S.C. § 352(bb)]Selling and shipping these misbranded drugs across state lines is a prohibited act.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce and delivering them is also prohibited.
FD&C Act § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Thrivelab must send a written response to FDA's Office of Compounding Quality and Compliance within 15 business days, identifying who makes the compounded drugs, providing sample labeling, and correcting or removing the misleading website claims.
Who should pay attention
- telehealth companies selling compounded semaglutide or other GLP-1 drugs
- compounding pharmacies whose products are marketed by partner websites
- marketing and regulatory reviewers who approve drug claims on company websites
This is a summary. Read the original letter on fda.gov.